A national collaborative study of the in vitro activity of oral cephalosporins and loracarbef (LY 163892)

References

• Guthikonda RN, Cama LD, Christensen BG. Total synthesis of beta-lactam antibiotics. VIII. Stereospecific total synthesis of (±)-1-carbacephalothin. J Am Chem Soc 1974; 96: 7584–7585
   PubMed Web of Science ®Google Scholar
• Blaszczak, LC, Brown, RF, Cook, GK, et al. Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins. J Med Chem 1990; 331: 656–662
   Google Scholar
• DeSante KA, Zeckel MY. Pharmacokinetic profile of loracarbef. Am J Med 1992; 92(Suppl 6A)165–196
   Google Scholar
• Coa C, Chin NX, Neu HC. In vitro activity and β-lactamase stability of LY 163892. J Antimicrob Chemother 1988; 22: 155–165
   Web of Science ®Google Scholar
• Jorgensen, JH, Redding, JS, Maher, LA, et al. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol 1987; 25: 2105–2113
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A2. NCCLS, Villanova, PA 1991
   Google Scholar
• Pelosi E, Fontana R. In vitro activity and β-lactamase stability of LY 163892. Eur J Clin Microbiol Infect Dis 1988; 7: 549–551
   PubMed Web of Science ®Google Scholar
• Jones R, Barry A. β-lactamase hydrolysis and inhibition studies of the new 7-carbacephem LY 163892. Eur J Clin Microbiol Infect Dis 1987; 6: 570–571
   Web of Science ®Google Scholar
• Turnidge J, Bell J. National antimicrobial resistance surveillance program. Australian Government Publishing Service, Canberra, ACT 1992, National Health and Medical Research Council, 1994
   Google Scholar
• Kitzis M-D, Liassine N, Ferre B, Gutman L, Acar JF, Goldstein K. In vitro activities of 15 oral β-lactams against Klebsiella pneumoniae harbouring new extended-spectrum β-lactamases. Antimicrob Agents Chemother 1990; 34: 1783–1786
   PubMed Web of Science ®Google Scholar
• Arguedas A, Arrietta A, Stutman H, Akaniro J, Marks M. In vitro activity of cefprozil (BMY 28100) and loracarbef (LY 163892) against pathogens obtained from middle ear fluid. J Antimicrob Chemother 1991; 27: 311–318
   PubMed Web of Science ®Google Scholar
• Doem G, Vautour R, Parker D, Tubert T, Torres B. In vitro activity of loracarbef (LY 163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 1991; 35: 1504–1507
   PubMed Web of Science ®Google Scholar
• Howard A, Dunkin K. Comparative in vitro activity of a new oral carbacephem, LY 163892. J Antimicrob Chemother 1988; 22: 445–456
   PubMed Web of Science ®Google Scholar
• Knappe C, Washington J. In vitro activities of LY 163892, cefaclor and cefuroxime. Antimicrob Agents Chemother 1988; 32: 131–133
   PubMed Web of Science ®Google Scholar
• Shelton S, Nelson J. In vitro susceptibilities of common pediatric pathogens to LY 163892. Antimicrob Agents Chemother 1988; 32: 268–270
   PubMed Web of Science ®Google Scholar
• Weneman W, Kibsey P, Gratton C, Knight V. In vitro activity of LY 163892 against pathogens isolated from pediatric patients. Eur J Clin Microbiol Infect Dis 1988; 7: 434–436
   PubMed Web of Science ®Google Scholar
• Mazzulli T, Simor A, Jaeger R, Fuller S, Low D. Comparative in vitro activities of several new fluoroquinolones and β-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1990; 34: 467–469
   PubMed Web of Science ®Google Scholar
• Nelson JD, Shelton S, Kusmiesz H. Pharmacokinetics of LY 163892 in infants and children. Antimicrob Agent Chemother 1988; 32: 1738–1739
   PubMed Web of Science ®Google Scholar
• Mason EO, Lamberth L, Lichenstein R, Kaplan SL. Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in vitro susceptibility to selected oral agents. J Antimicrob Chemother 1995; 36: 1043–1048
   PubMed Web of Science ®Google Scholar
• Van der Auwera P. Bactericidal titers of loracarbef (LY 163892) in serum and killing rates in volunteers receiving 400 versus 200 milligrams. Antimicrob Agents Chemother 1992; 36: 521–526
   PubMed Web of Science ®Google Scholar
• Lees AS, Andrews JM, Wise R. The pharmacokinetics, tissue penetration and in vitro activity of loracarbef, a β-lactam antibiotic of the carbacephem class. J Antimicrob Chemother 1993; 32: 853–859
   PubMed Web of Science ®Google Scholar